B+
Bull case
25%
Probability
Target price
$40.00
+64.7% vs current
GLSI
Greenwich LifeSciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$24.00
-1.2% vs current
B-
Bear case
25%
Probability
Target price
$12.00
-50.6% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+51.8
Score
AI commentary
Sentiment is cautiously constructive but no longer strong. Primary-source evidence improved with January-March 2026 company updates on manufacturing, screening, and preliminary recurrence trends, yet the deterministic prior is now neutral with lower evidence quality, and the most recent filed 10-Q still carries substantial doubt language and low reported cash at September 30, 2025 [#10-Q-2025-11-14]. This looks more like a monitored, event-driven clinical setup than a clean momentum long.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystValidation of January cash build versus ongoing dilutionHigh impact
The company said the ATM funded a January 2026 cash balance of about $12.5 million and could lessen the need for a large near-term financing, but the latest 10-Q still showed $3.8 million of cash at September 30, 2025 and disclosed substantial doubt about continuing as a going concern, so the next financing/runway confirmation is a meaningful near-term swing factor [#PR-2026-01-27] [#10-Q-2025-11-14].
2026-09-17eventAdditional open-label FLAMINGO-01 data update or conference presentationHigh impact
Management's March 17, 2026 update said the fully enrolled 250-patient non-HLA-A*02 arm showed a preliminary 0.7% annual recurrence rate over 1.2 patient-years versus a 4% historical comparator and noted that future updates may be presented at upcoming conferences; because the dataset is still preliminary and company-reported, outside validation or continued clean data maturation could move the stock materially [#PR-2026-03-17].
2027-06-30catalystBlinded FLAMINGO-01 event accrual toward interim analysis and BLA-enabling manufacturing readinessHigh impact
January and March 2026 company updates said screening has exceeded 1,000 patients, annualized screen rate rose above 800 patients, the open-label arm is fully enrolled, FDA approved use of the first commercial GP2 lot in FLAMINGO-01, and the Phase III design calls for 28 events with an interim analysis at 14; steady event accrual plus additional commercial-lot manufacturing would be the clearest path to real de-risking, but timing remains uncertain and likely multi-quarter [#PR-2026-01-22] [#PR-2026-03-03].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology